Article Text

Download PDFPDF
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding The Swedish Medical Products Agency, The IMI project BT-CURE (Grant agreement No. 115142-1) and the Biobanking and Molecular Resource Infrastructure of Sweden (

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Data of this study are open for access.